PAVmed Revenue Per Share vs Capex To Revenue Analysis
PAVM Stock | USD 1.18 0.07 6.31% |
PAVmed financial indicator trend analysis is much more than just breaking down PAVmed Inc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether PAVmed Inc is a good investment. Please check the relationship between PAVmed Revenue Per Share and its Capex To Revenue accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PAVmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
Revenue Per Share vs Capex To Revenue
Revenue Per Share vs Capex To Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of PAVmed Inc Revenue Per Share account and Capex To Revenue. At this time, the significance of the direction appears to have pay attention.
The correlation between PAVmed's Revenue Per Share and Capex To Revenue is -0.98. Overlapping area represents the amount of variation of Revenue Per Share that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of PAVmed Inc, assuming nothing else is changed. The correlation between historical values of PAVmed's Revenue Per Share and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Revenue Per Share of PAVmed Inc are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Revenue Per Share i.e., PAVmed's Revenue Per Share and Capex To Revenue go up and down completely randomly.
Correlation Coefficient | -0.98 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Revenue Per Share
The amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding.Capex To Revenue
The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.Most indicators from PAVmed's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into PAVmed Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PAVmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. At this time, PAVmed's Selling General Administrative is very stable compared to the past year. As of the 3rd of December 2024, Issuance Of Capital Stock is likely to grow to about 29.4 M, while Enterprise Value Over EBITDA is likely to drop (0.82).
2023 | 2024 (projected) | Total Operating Expenses | 64.8M | 68.1M | Non Recurring | 236.9K | 210.6K |
PAVmed fundamental ratios Correlations
Click cells to compare fundamentals
PAVmed Account Relationship Matchups
High Positive Relationship
High Negative Relationship
PAVmed fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 7.2M | 19.8M | 87.0M | 54.0M | 33.1M | 23.6M | |
Other Current Liab | 1.4M | (15.0M) | 4.3M | 3.7M | 6.6M | 7.0M | |
Total Current Liabilities | 11.9M | 20.0M | 7.6M | 41.2M | 54.2M | 56.9M | |
Total Stockholder Equity | (3.8M) | 1.9M | 61.7M | (9.7M) | (53.8M) | (51.1M) | |
Net Tangible Assets | (6.1M) | (641K) | 57.2M | (15.8M) | (18.2M) | (17.3M) | |
Net Debt | 1.9M | (2.3M) | (77.3M) | (3.1M) | 29.1M | 30.5M | |
Retained Earnings | (53.7M) | (88.3M) | (138.9M) | (228.2M) | (294.4M) | (279.7M) | |
Accounts Payable | 2.4M | 3.0M | 3.3M | 2.7M | 1.8M | 1.9M | |
Cash | 6.2M | 17.3M | 77.3M | 39.7M | 19.6M | 18.9M | |
Cash And Short Term Investments | 6.2M | 17.3M | 77.3M | 39.7M | 19.6M | 18.9M | |
Common Stock Total Equity | 27.1K | 40.5K | 64K | 86K | 98.9K | 103.8K | |
Common Stock Shares Outstanding | 2.0M | 3.2M | 5.2M | 5.9M | 7.2M | 6.9M | |
Liabilities And Stockholders Equity | 7.2M | 19.8M | 87.0M | 54.0M | 33.1M | 23.6M | |
Capital Surpluse | 32.6M | 47.6M | 87.6M | 198.1M | 227.8M | 239.2M | |
Other Current Assets | 328.3B | 1.7M | 5.2M | 3.9M | 3.8M | 3.6M | |
Other Stockholder Equity | 47.6M | 87.6M | 198.1M | 215.9M | 237.6M | 249.5M | |
Total Liab | 11.9M | 20.3M | 7.6M | 43.0M | 57.1M | 60.0M | |
Total Current Assets | 6.5M | 18.9M | 82.6M | 43.9M | 24.5M | 20.8M | |
Common Stock | 40.5K | 64K | 86K | 95K | 9K | 8.6K | |
Non Current Assets Total | 692.9K | 837K | 4.3M | 10.1M | 8.6M | 9.1M | |
Non Currrent Assets Other | 692.9K | 755K | 725K | 1.1M | 1.1M | 614.4K | |
Other Assets | 693K | 837K | 725K | 1.1M | 1.0 | 0.95 | |
Non Current Liabilities Total | 10.5M | 300K | 4.3B | 1.8M | 3.0M | 2.8M | |
Noncontrolling Interest In Consolidated Entity | (161.5K) | (814.3K) | (2.4M) | 17.8M | 20.4M | 21.4M | |
Retained Earnings Total Equity | (37.0M) | (53.7M) | (88.3M) | (138.9M) | (125.0M) | (118.8M) | |
Short Term Investments | 34K | 262K | 2.0M | 3.0M | 2.7M | 2.8M | |
Preferred Stock Total Equity | 2.0M | 2.3M | 2.5M | 2.4M | 2.8M | 1.9M | |
Property Plant Equipment | 692.9K | 82K | 1.6M | 5.5M | 6.3M | 6.6M | |
Short Long Term Debt Total | 7.9M | 8.1M | 15.0M | 36.6M | 48.7M | 51.2M | |
Net Invested Capital | 2.0M | 14.3M | 59.2M | 21.3M | (12.6M) | (12.0M) | |
Short Long Term Debt | 7.9M | 8.1M | 14.7M | 33.7M | 44.2M | 46.4M | |
Net Working Capital | (5.3M) | (1.0M) | 75.1M | 2.7M | (29.7M) | (28.2M) | |
Short Term Debt | 7.9M | 8.1M | 15.0M | 34.8M | 45.8M | 48.1M | |
Capital Stock | 2.3M | 2.6M | 2.5M | 2.8M | 3.0M | 2.8M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PAVmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PAVmed. If investors know PAVmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PAVmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.14) | Revenue Per Share 0.459 | Quarterly Revenue Growth 4.898 | Return On Assets (0.80) | Return On Equity (13.58) |
The market value of PAVmed Inc is measured differently than its book value, which is the value of PAVmed that is recorded on the company's balance sheet. Investors also form their own opinion of PAVmed's value that differs from its market value or its book value, called intrinsic value, which is PAVmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PAVmed's market value can be influenced by many factors that don't directly affect PAVmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PAVmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if PAVmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PAVmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.